Xeris Biopharma (NASDAQ:XERS) Stock Keeps “Neutral” Rating at Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Xeris Biopharma (NASDAQ:XERS) in a research note issued to investors on Friday,Benzinga reports. The firm currently has a $12.00 target price on the stock, up from their prior target price of $8.00.

Several other equities analysts have also commented on XERS. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays increased their price target on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Leerink Partners lifted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright upped their price objective on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Friday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.20.

Xeris Biopharma Trading Up 16.2%

XERS traded up $2.12 during midday trading on Friday, hitting $15.20. The company’s stock had a trading volume of 7,895,311 shares, compared to its average volume of 2,146,978. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a market cap of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61. The firm has a 50-day moving average price of $9.62 and a two-hundred day moving average price of $7.62. Xeris Biopharma has a 52-week low of $5.25 and a 52-week high of $15.21.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, research analysts anticipate that Xeris Biopharma will post 0.07 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the sale, the insider owned 1,086,130 shares of the company’s stock, valued at approximately $11,111,109.90. This represents a 2.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the sale, the insider directly owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. This trade represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently made changes to their positions in the business. Chicago Partners Investment Group LLC raised its stake in shares of Xeris Biopharma by 16.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 13,286 shares of the company’s stock valued at $136,000 after acquiring an additional 1,861 shares during the period. AlphaCentric Advisors LLC boosted its position in Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock worth $464,000 after purchasing an additional 1,940 shares during the period. Allworth Financial LP boosted its position in Xeris Biopharma by 86.4% during the 2nd quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares during the period. Jacksonville Wealth Management LLC increased its holdings in Xeris Biopharma by 11.8% in the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $182,000 after purchasing an additional 2,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 7.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,266 shares of the company’s stock valued at $332,000 after purchasing an additional 2,190 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.